Canada Markets closed

Ceapro Inc. (CRPOF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.44690.0000 (0.00%)
At close: 03:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.4469
Open0.4469
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4469 - 0.4469
52 Week Range0.4200 - 0.7270
Volume1,715
Avg. Volume7,011
Market Cap34.712M
Beta (5Y Monthly)1.50
PE Ratio (TTM)40.63
EPS (TTM)0.0110
Earnings DateApr. 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ceapro Inc. Announces R&D Funding to Support PGX Technology Project

    – PGX Technology further recognized as a disruptive technology – Additional support paves the way for the manufacturing of pharmaceutical-grade yeast beta glucan (YBG) EDMONTON, Alberta, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced they are receiving advisory services and up to

  • GlobeNewswire

    Ceapro Inc. Reports 2021 Third Quarter and Nine-Month Financial Results and Operational Highlights

    – Increased R&D activities focused on the completion of a clinical trial for oat beta glucan as a potential cholesterol reducer and on the development of yeast beta glucan as a potential inhalable therapeutic for COVID-19 – – Q3 2021 record sales of $4,523,000 compared to $3,476,000 for Q3 2020, representing a 30% increase – – Net profit of $875,000 for Q3 2021 vs. net profit of $192,000 for Q3 2020, a 356% increase – – Achieved record production levels despite COVID-19 pandemic situation – EDMO

  • GlobeNewswire

    Ceapro Inc. Reports Preliminary Results from Clinical Trial Evaluating Oat Beta Glucan in Patients with High Cholesterol Levels

    EDMONTON, Alberta, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today reported preliminary results from the clinical study entitled “A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Compare the Efficacy and Safety of High-Medium Molecular Weight Beta-Glucan a